Patents Examined by M Franco G Salvoza
  • Patent number: 11382970
    Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of insect bite hypersensitivity of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating insect bite hypersensitivity of equine mammals, preferably of horses.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: July 12, 2022
    Assignee: UNIVERSITAT ZURICH
    Inventors: Antonia Fettelschoss, Martin Bachmann
  • Patent number: 11377669
    Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: July 5, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 11369578
    Abstract: The present disclosure relates to nanoemulsion compositions with certain surfactant blend ratios that impart enhanced permeability. Such compositions are useful for topical, mucosal and intranasal applications and allow for the greater delivery of one or more active agents to the application site to prevent infection by a microorganism.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 28, 2022
    Assignee: BlueWillow Biologics, Inc.
    Inventor: Susan Ciotti
  • Patent number: 11360090
    Abstract: A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: June 14, 2022
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. Newman, Sam Anyanwu
  • Patent number: 11344616
    Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include mutant M2 sequences, mutant BM2 sequences, and are useful in immunogenic compositions, e.g., as a quadrivalent vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 31, 2022
    Assignee: FluGen, Inc.
    Inventors: Michael J. Moser, Yasuko Hatta, Pamuk Bilsel
  • Patent number: 11331378
    Abstract: The present disclosure provides methods for prophylactically treating a subject for viral infections comprising topically administering a ranpirnase composition. The disclosure also provides compositions that could be used for prophylactic treatment.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: May 17, 2022
    Assignee: ORGENESIS INC.
    Inventors: Luis Squiquera, Thomas Hodge, Jamie Sulley
  • Patent number: 11325966
    Abstract: This invention relates to broadly neutralizing and potent anti-HIV-1 antibodies, kits, and methods of use thereof.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 10, 2022
    Assignees: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Natalia T. Freund, Pamela J. Bjorkman, Louise Scharf
  • Patent number: 11324819
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 10, 2022
    Assignees: University of Washington, Abacus Bioscience, Inc.
    Inventors: Edward Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
  • Patent number: 11324788
    Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 10, 2022
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane Dinsart, Michael Dahm, Ottheinz Krebs
  • Patent number: 11311487
    Abstract: Combining viral vector with surfactant preserves vector infectivity, and surfactant provided an unexpected benefit by protecting viral vector from damage due to transient elevated temperature.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: April 26, 2022
    Assignee: Trizell Ltd.
    Inventors: Minna Hassinen, Robert Shaw, Nigel Parker
  • Patent number: 11300565
    Abstract: A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: April 12, 2022
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Gale W. Newman, Sam Anyanwu
  • Patent number: 11267847
    Abstract: The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: March 8, 2022
    Assignees: Medigene AG, Deutsches Krebsforschungszentrum
    Inventors: Florian Sonntag, Juergen Kleinschmidt, Markus Hoerer, Kerstin Pino Tossi
  • Patent number: 11260090
    Abstract: Provided are modified arenaviruses and populations thereof, wherein the modified arenaviruses include i) an introduced PPXY domain; ii) an increased number of PPXY domains; iii) a substituted amino acid in place of S41 in a viral Z protein that is not a substrate for a serine or tyrosine kinase, or a combination of i)-iii). A PPXY domain can include a phosphomimetic replacement of the Y amino acid. Modified Old World and New World arenaviruses are included. Arenavirus production is provided using cell cultures that contain a kinase inhibitor that inhibits a kinase that can phosphorylate the Y amino acid of the PPXY domain, or by cells that have disrupted kinase gene expression, or by cells that have a disrupted ESCRT system. Also provided are pharmaceutical formulations that contain modified arenaviruses, and methods of using such formulations for stimulating an immune response hat is fully or partially protective against arenavirus infection.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 1, 2022
    Assignee: University of Vermont and State Agricultural College
    Inventors: Emily Adaline Bruce, Jason William Botten, Christopher Michael Ziegler
  • Patent number: 11253586
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: February 22, 2022
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • Patent number: 11254953
    Abstract: The present disclosure relates to compositions and methods for investigating Zika virus (ZIKV) biology and pathogenicity. The present disclosure provides genetically stable viral vectors to produce functional RNA transcripts of ZIKV cDNAs. In particular, the present disclosure provides full-length infectious cDNAs as bacterial artificial chromosomes for spatiotemporally distinct and genetically divergent ZIKVs. The present disclosure also provides methods of generating a genetically engineered attenuated ZIKV using the genetically stable viral vectors described herein.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 22, 2022
    Assignee: Utah State University
    Inventor: Young-Min Lee
  • Patent number: 11254712
    Abstract: Disclosed are chimeric polypeptides based on viral membrane fusion proteins. More particularly, the present invention discloses chimeric polypeptides that comprise a virion surface exposed portion of a viral fusion protein and a heterologous structure-stabilizing moiety, and to complexes of those chimeric polypeptides. The present invention also discloses the use of these complexes in compositions and methods for eliciting an immune response to a fusion protein of an enveloped virus, or complex of the fusion protein, and/or for treating or preventing an enveloped virus infection. The present invention further discloses the use of the heterologous structure-stabilizing moiety for oligomerizing heterologous molecules of interest.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: February 22, 2022
    Assignee: The University of Queensland
    Inventors: Keith Joseph Chappell, Daniel Watterson, Paul Robert Young
  • Patent number: 11254733
    Abstract: Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: February 22, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Peter Palese, Florian Krammer, Teddy John Wohlbold, Adolfo Garcia-Sastre
  • Patent number: 11207390
    Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of a condition or disorder selected from a pruritic condition or an allergic condition, of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating pruritus, preferably pruritus associated with a pruritic condition or an allergic condition such as allergic dermatitis, of equine mammals, preferably of horses.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: December 28, 2021
    Assignees: UNIVERSITÄT ZÜRICH, EVAX AG, UNIVERSITÄT BERN
    Inventors: Antonia Fettelschoss, Victoria Fettelschoss, Martin Bachmann
  • Patent number: 11208630
    Abstract: Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: December 28, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Nathalie Clement, Barry John Byrne, Laura A. Small
  • Patent number: 11203740
    Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: December 21, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CHU NANTES, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
    Inventor: Nicole Brument